Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor - PubMed (original) (raw)
Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor
D Vercammen et al. J Exp Med. 1998.
Abstract
Murine L929 fibrosarcoma cells treated with tumor necrosis factor (TNF) rapidly die in a necrotic way, due to excessive formation of reactive oxygen intermediates. We investigated the role of caspases in the necrotic cell death pathway. When the cytokine response modifier A (CrmA), a serpin-like caspase inhibitor of viral origin, was stably overexpressed in L929 cells, the latter became 1,000-fold more sensitive to TNF-mediated cell death. In addition, TNF sensitization was also observed when the cells were pretreated with Ac-YVAD-cmk or zDEVD-fmk, which inhibits caspase-1- and caspase-3-like proteases, respectively. zVAD-fmk and zD-fmk, two broad-spectrum inhibitors of caspases, also rendered the cells more sensitive, since the half-maximal dose for TNF-mediated necrosis decreased by a factor of 1,000. The presence of zVAD-fmk also resulted in a more rapid increase of TNF-mediated production of oxygen radicals. zVAD-fmk-dependent sensitization of TNF cytotoxicity could be completely inhibited by the oxygen radical scavenger butylated hydroxyanisole. These results indicate an involvement of caspases in protection against TNF-induced formation of oxygen radicals and necrosis.
Figures
Figure 1
CrmA expression enhances TNF-induced necrosis. (A) Western blot analysis of transfected L929 clones. Lane 1, control L929 cells transfected with pSV2neo alone; lanes 2–4, different clones cotransfected with pCAGGS CrmA and pSV2neo. Arrowhead, CrmA expression. (B) Sensitizing effect on TNF-mediated necrosis in L929 cells. ▿, control; •, clone 2; ○, clone 5; and ▾, clone 12.
Figure 1
CrmA expression enhances TNF-induced necrosis. (A) Western blot analysis of transfected L929 clones. Lane 1, control L929 cells transfected with pSV2neo alone; lanes 2–4, different clones cotransfected with pCAGGS CrmA and pSV2neo. Arrowhead, CrmA expression. (B) Sensitizing effect on TNF-mediated necrosis in L929 cells. ▿, control; •, clone 2; ○, clone 5; and ▾, clone 12.
Figure 2
Sensitizing effect of peptide caspase inhibitors on TNF-induced necrosis in L929 cells, added 2 h before TNF treatment. (A) Without addition of BHA. •, Ac-YVAD-cmk (100 μM); ○, zDEVD-fmk (100 μM); ▾, Ac-YVAD-cmk + zDEVD-fmk (100 μM each); ▿, zVAD-fmk (25 μM); ▪, zD-fmk (25 μM); □, zAAD-cmk (100 μM); and ♦, control. (B) With BHA (100 μM) added at the same time as TNF (same symbols as in A).
Figure 2
Sensitizing effect of peptide caspase inhibitors on TNF-induced necrosis in L929 cells, added 2 h before TNF treatment. (A) Without addition of BHA. •, Ac-YVAD-cmk (100 μM); ○, zDEVD-fmk (100 μM); ▾, Ac-YVAD-cmk + zDEVD-fmk (100 μM each); ▿, zVAD-fmk (25 μM); ▪, zD-fmk (25 μM); □, zAAD-cmk (100 μM); and ♦, control. (B) With BHA (100 μM) added at the same time as TNF (same symbols as in A).
Figure 3
Effect of zVAD-fmk on TNF-induced reactive oxygen formation and cell death. (A) Effect on TNF-induced oxygen radical production (relative DHR123 fluorescence as compared to untreated cells). •, TNF alone (500 IU/ml); ○, TNF + BHA (100 μM); ▾, TNF + zVAD-fmk (25 μM); ▿, TNF + zVAD-fmk + BHA; and ▪, zVAD-fmk alone. (B) Effect on TNF-induced cell killing determined on the basis of PI-negative cells (same experiment and symbols as in A).
Figure 3
Effect of zVAD-fmk on TNF-induced reactive oxygen formation and cell death. (A) Effect on TNF-induced oxygen radical production (relative DHR123 fluorescence as compared to untreated cells). •, TNF alone (500 IU/ml); ○, TNF + BHA (100 μM); ▾, TNF + zVAD-fmk (25 μM); ▿, TNF + zVAD-fmk + BHA; and ▪, zVAD-fmk alone. (B) Effect on TNF-induced cell killing determined on the basis of PI-negative cells (same experiment and symbols as in A).
Figure 4
Effect of zVAD-fmk on radical scavenging in L929 cells. (A) zVAD-fmk does not alter free thiol concentrations. Cells were treated with zVAD-fmk (25 μM) for 4 h [zVAD-fmk (-4)] or 2 h [zVAD-fmk (-2)] before TNF addition, or with DEM 3 h after TNF addition. Open bars, without TNF; filled bars, 1,000 IU/ml TNF. (B) Effect of zVAD-fmk on H2O2- or tBuOOH-induced oxygen radical production (relative DHR123 fluorescence as compared to untreated cells). •, H2O2 (50 μM); ○, H2O2 + zVAD-fmk (25 μM); ▾, tBuOOH (100 μM); ▿, tBuOOH + zVAD-fmk; and ▪, zVAD-fmk alone.
Figure 4
Effect of zVAD-fmk on radical scavenging in L929 cells. (A) zVAD-fmk does not alter free thiol concentrations. Cells were treated with zVAD-fmk (25 μM) for 4 h [zVAD-fmk (-4)] or 2 h [zVAD-fmk (-2)] before TNF addition, or with DEM 3 h after TNF addition. Open bars, without TNF; filled bars, 1,000 IU/ml TNF. (B) Effect of zVAD-fmk on H2O2- or tBuOOH-induced oxygen radical production (relative DHR123 fluorescence as compared to untreated cells). •, H2O2 (50 μM); ○, H2O2 + zVAD-fmk (25 μM); ▾, tBuOOH (100 μM); ▿, tBuOOH + zVAD-fmk; and ▪, zVAD-fmk alone.
Figure 5
Inhibitory effect of zVAD-fmk on TNF-mediated apoptosis in HeLa H21 cells (• and ○; 1 μg/ml actinomycin D added) and KYM cells (▾ and ▿). Open symbols, TNF only; closed symbols, 25 μM zVAD-fmk added 2 h before TNF treatment.
Figure 6
Possible mechanisms of action in caspase inhibitor-mediated sensitization of TNF-induced necrosis in L929 cells. A putative caspase (CASP-X ), inhibited by CrmA or zVAD-fmk, acts as a negative regulator of premitochondrial signaling (1) or mitochondrial production of reactive oxygen intermediates (ROI; 2). Alternatively, damaging of mitochondria by ROI could impair normal functioning, resulting in an even higher radical production; normally, the cell possesses a mechanism to remove these damaged mitochondria by a process involving one or more caspases (3). Interference with this clean-up process enhances necrosis.
References
- Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411–452. - PubMed
- Fiers, W. 1995. Biologic therapy with TNF: preclinical studies. In Biologic Therapy of Cancer. 2nd ed. V.T. DeVita, Jr., S. Hellman, and S.A. Rosenberg, editors. J.B. Lippincott, Philadelphia. 295–327.
- Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabeele P, Fiers W. Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett. 1997;410:96–106. - PubMed
- Grooten J, Goossens V, Vanhaesebroeck B, Fiers W. Cell membrane permeabilization and cellular collapse, followed by loss of dehydrogenase activity: early events in tumour necrosis factor–induced cytotoxicity. Cytokine. 1993;5:546–555. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous